Global Hereditary Angioedema Market: Overview

Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the U.S. and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.

Another factor stoking growth in the market is the rise in hereditary angioedema (HAE) attacks. The frequency and severity of HAE attacks is found to be increased with triggers such as stress, anxiety, minor surgeries, hormone replacement therapies and ACE inhibitors used for treatment of hypertension. According to World Allergy Organization, an estimated 40 million people are receiving ACE inhibitor treatment annually.

Posing a hindrance to the market is the few approved specialty HAE drugs that are expensive. As a result patients mostly opt for conventional drugs, thus hampering the global hereditary angioedema market.

A report by Transparency Market Research finds that the global hereditary angioedema market will likely become worth US$3.81 bn by 2025 from US$ 1.73 bn in 2016 by registering a strong 9.1% CAGR from 2017 to 2025.


hereditary angioedema market


Rise of Innovative Products to Help C1 Esterase Inhibitor Segment Retain Market Leading Share

The global hereditary angioedema market can be classified on the basis of the class of drugs into C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, and others such as conventional and pipeline. The C1 esterase inhibitor can be further divided into drugs such as Cinryze, Berinert, and Ruconest. Among them, C1 esterase inhibitor, accounted for more than half the share in the market in 2016 and going forward too, the segment is slated to dominate the market on account of its use in prophylactic treatment and acute HAE attack treatment. The emergence of novel products will aid the segment to hold on to its leading share in the future. This is forecasted to clock a CAGR of 4.3% from 2017 to 2025.

Uptake of Specialty Drugs for Treatment Boosts North America Market

North America, Europe and the Rest of the World are the three key geographical segments in the global hereditary angioedema market. North America, of them, is the leading region which is projected to rise at a healthy CAGR of 8.3% from 2017 to 2025 to retain its dominance in the near future. Reasons for the region’s leading position is a highly developed healthcare infrastructure and strong support from public and private sector in terms of reimbursements. Besides, rise in awareness about hereditary angioedema among patients has led to improvements in diagnosis and adoption of specialty drugs for treatment. This is also predicted to boost the market.

Europe trails North America in terms of market share in the global hereditary angioedema market. The market in the region is forecasted to rise at a CAGR of 10.8% between 2017 and 2025. So far, slow approvals, dearth of awareness about the condition and delay in re-imbursement for treatment has acted as roadblock to the market in Europe. However, with about an estimated 2000 hereditary angioedema patients in Germany and the U.K., the market seems to have ample room for growth.

Some of the important vendors in the global hereditary angioedema market are Pharming Group NV, Shire plc, CSL Limited, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc.


Global Hereditary Angioedema Market: Scope and Methodology

This report on the global hereditary angioedema market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2017 to 2025, considering the macro and micro environmental factors. Growth rates for each segment within the global hereditary angioedema market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global hereditary angioedema market.

Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of product features of different types of drug class and various pipeline products. Additionally, market related factors such as rise in preference for self-administrable drugs, expiry of market exclusivity of certain drugs, projected launch of the drugs etc. in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Hereditary Angioedema Market: Segmentation

Hereditary Angioedema is a rare genetic disease that is caused by lack or abnormal functioning of the protein C1 inhibitor protein. Lack of functional C1 inhibitor protein leads to high volume of bradykinin, which triggers of blood vessels causing inflammation of body organs. HAE symptoms are often misdiagnosed for common allergies or abdominal pain. Many patients are hospitalized due to HAE attacks. HAE attack in upper airway have proven to be fatal if untreated on its emergence.

Based on drug class, the global hereditary angioedema market has been segmented into C1 esterase inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor others. The C1 esterase inhibitor is further segmented into drugs namely Cinryze, Berinert and Ruconest. The segment is anticipated to hold a significant share of the global market. The others segment is further sun segmented into conventional and pipeline products. The segment is projected to dominate the market during the forecast period due to launch of novel products.

Based on route of administration, the global hereditary angioedema market is segmented into intravenous, subcutaneous injections and oral. The subcutaneous injections is anticipated to dominate the market during the forecast period due to availability of approved drugs for acute HAE attack are administered subcutaneously, development of variants of Cinryze and Berinert that can be administered subcutaneously etc.

Based on the distribution channel, the global hereditary angioedema market is segmented into hospital pharmacies, retail pharmacies and others.    Ever increasing number of retail pharmacies is attributed for the significant share of the segment in the global market.

Hereditary Angioedema Market: Geographical and Competitive Dynamics

Geographically, the global hereditary angioedema market has been segmented into six regions: North America, Europe, Asia Pacific and Rest of the World. In addition, the regions have been further segmented by major countries from each region.

The report also profiles major players in the hereditary angioedema market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc. and iBio, Inc.

The global hereditary angioedema market has been segmented as below:

Global Hereditary Angioedema Market, by Drug Class

  • C1 Esterase Inhibitor
    • Cinryze
    • Berinert
    • Ruconest
  • Selective Bradykinin B2 Receptor Antagonist
    • Firazyr
  • Kallikrein Inhibitor
    • Kalbitor
  • Others
    • Conventional Drugs (attenuated androgens, antifibrinolytic agents
    • Pipeline Products (DX-2930, BCX-7353)

Global Hereditary Angioedema Market, by Route of Administration

  • Intravenous
  • Subcutaneous Injection
  • Oral

Global Hereditary angioedema Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Global Hereditary Angioedema Market, by Geography

  • North America
  • Europe
  • Rest of the World